INDEX

Note: Locators followed by ‘f’ and ‘t’ refer to figures and tables, respectively

1H-magnetic resonance spectroscopy, 154
3.0 tesla (3T), MRI, 77
8-10 electrode array, 32, 32f
10-20 system, 32, 32f, 44, 47–48
11-electrode system, 48
19-channel EEG, 47–48

A
abnormal posture, 163
acute seizures, 56, 100
adrenocorticotrophic hormone (ACTH), 109
AED. See antiepileptic drugs (AEDs)
a-EEG/EEG method, 46
artefacts, 43
limitations, 41
montage, 47
performance for seizure detection, 47–50,
49–50
sensitivity for detecting seizures, 49
uses, 40
see also amplitude-integrated EEG (a-EEG)
aetiologies, 128
EEG for clues to, 22–23
genetic, 157
of neonatal seizures, 117–118, 118f
neurodevelopmental outcomes in infants with
NS, 152–154, 155f
neuropathological process, 155
albumin, 181
Alpers-Huttenlocher syndrome, 87
α-amino-3-hydroxy-5-methyl-4-isoxazole
propionate receptors (AMPARs), 6, 8,
174–175
American Clinical Neurophysiology Society's
guideline, 116
ammonia, deleterious effects of, 89
amplitude-integrated EEG (a-EEG), 16, 24, 40,
56–57, 117, 147, 157
display, 57f
electrodes, 44
epileptic seizure activity, 42f, 43
features, 41
method, 41, 43–44
modern machines, 57
monitoring infants at high risk, 51
performance for seizure detection, 47–50
seizure detection alarm, 46f
standard v-EEG and, 25
subclinical seizures detection in infants at high
risk, 46–47
two-channel recording, 45f
antenatal neurological injury, 24
anticonvulsants, 129, 132, 175, 182
antiepileptic drugs (AEDs), 7, 19, 31, 51, 100–101,
104, 128, 150, 165, 172
duration of, 138
first-line, 129–132
for neonatal seizures, 130t
neurodevelopmental outcomes of NS, 166–167
novel, 172
second- and third-line, 133–135
in therapeutic targets of neonatal seizures,
181–182
anti-inflammatory compounds/drugs, 132, 185
antiquitin deficiency, 137, 154
apoptosis, 181–182
apoptosis inducing factor (AIF), 173
apparent diffusion coefficient (ADC), 77, 80
artefacts
a-EEG/EEG, 43
neonatal EEG, 60f
on v-EEG recording, 33f, 34, 35f, 37f, 38
Artemis 123, 93
arterial and venous strokes, 163
arterial ischemic stroke, 81, 81f, 154, 157
ARX gene (aristaless-related homebox gene), 107
asphyxia, 163, 173
autonomic instability, 163

B
Bahi-Buisson's cohort, 109
basal ganglia, 80
benign familial neonatal epilepsy (BFNE), 101
benign familial neonatal seizures (BFNS),
101–103
benign neonatal sleep myoclonus, 115
benzodiazepines, 134
BERDs (brief EEG rhythmic discharges), 21f, 22,
128
biomarkers, 157
biological defects, 88–89
black box approach, disadvantage of, 65
blood-brain barrier (BBB) breakdown, 181, 184–185
brain inflammation, 180, 185
brain injury, 78
brain malformations, 152
brain pathology, 172
brainstem injury, 155
‘brainstem release’ phenomena, 167
brief EEG rhythmic discharges (BERDs), 21f, 22, 128
brief tonic-spasms seizures, 108
bumetanide (BTN), 131–132, 178, 183–184
burst suppression in HIE, 152
patterns, 22, 23f, 105–106, 106f, 147

C
carbamazepine (CBZ), 135–136
cardiac toxicity, 134
caspase-dependent pathways, 173
caspase-independent pathways, 173
cell-based therapies, 185–186
central nervous system (CNS) infection, 83–84, 156
central server, 70
cerebral cortex, neonatal, 1–8
cortical development and seizures, 7–8
embryonic development, 1–2
excitability of cortical neurons, 4, 6
morphological changes in cortical neurons in neonatal and infant brain, 2–4, 2f, 3f
neurotransmitters in, 6–7
synaptic plasticity in developing, 4
cerebral function monitors (CFMs), 41
cerebral palsy, 167
cerebral parenchymal blood flow (CBF), 93
cerebrovascular injury, 78–83
arterial ischemic stroke, 81
HII, 78–80
term infants, 82
venous infarct and hemorrhage, 82
chemical biomarkers as predictors, 157
classification stage, NSDA, 64–65
classifier, 65
clinically diagnosed seizures, 12–14
clonazepam, 116, 134
cognitive impairment, 168
Color Doppler, 76–77
coma, 163
components of classifier, 65
Compumedics system, 34
computed tomography (CT), 76, 83, 122
congenital CMV, 84
congenital infection, 84
congenital malformations, 40
congenital toxoplasmosis, 84
conventional antiepileptic treatments, 110
cooling as neuroprotective strategy, 172
corpus callosum, 87
correlation analysis method, 64
cortical development, malformations of, 89–91
co-transporters of chloride, 175, 177–180
cranial ultrasound, 77, 120
creatine kinase-brain band, 157
cup electrodes, 31
cyclin-dependent kinase-like 5 (CDKL5)-associated epileptic encephalopathy, 101, 108

cysteine protease, 173
cytochrome C, 173
cytokines, 180
cytomegalovirus (CMV), 84

decision boundary, classifier, 65
deleterious effects of ammonia, 89
developmental disabilities, 168
diazepam, 134
diffuse correlation spectroscopy (DCS), 93
diffusion-weighted imaging (DWI), 81, 85
digital EEG signal, recording of, 58
digital systems, v-EEG, 34
DNA degradation, 173
Doppler ultrasound, resistive indices on, 79
drugs and therapies, neonatal seizures, 135–138
carbamazepine, 135–136
ketogenic diet, 138
lamotrigine, 136
metabolic disorders, 137–138
oxcarbazepine, 136
paraldehyde, 136
thiopentone, 137
topiramate, 129, 135
valproate, 135
vigabatrin, 136
vitamin responsive seizures, 137–138
xenon, 137
zonisamide, 136
dystonic movements, 116

early myoclonic encephalopathy (EME), 101, 105–107
echogenicity, 79
EEG. See electroencephalography/electroencephalogram (EEG)
EEG confirmed seizures (ECSz), 128
electroclinical dissociation (ECD), 19–20, 30, 40, 114, 131, 151, 181
electroclinical seizures, 146
clinical features, 13–14, 147–152
electrode application, 30–32, 31f
electroencephalography/electroencephalogram (EEG), 30, 56, 116–117, 146
Index

adequate skin preparation, 31
for assessment of response to therapeutic interventions, 22
asymmetric EEG due to infarcts, 150
background abnormality, 24, 147, 151, 165
burst suppression patterns, 147
for clues to underlying aetiology, 22–23 correlates, 13
for detection of seizures, 59
electroclinical syndromes, 147
electrode application, 30–32, 31
epoch, electro-cerebral inactivity, 153
for estimation of seizure burden, 22 features, 13, 24, 59
FFA, 20, 20
filter settings for, 34
frequencies of neonatal, 58
generation, 64
ictal, 100–101, 102, 103, 104
interictal, 100–101, 105
montages and filters for, 34, 36
neonatal EEG artefacts, 60
neurodevelopmental outcomes in infants with NS, 146–147
normal, 148
preterm, 149
problem with amplitude, 64
for prognosis, 23–24
pseudo-periodicity in, 61–62
recording of digital signal, 58
seizures in neonates, 14, 14f, 15f, 16–17, 16f, 18f, 19, 19f
simplified version of, 57
electrographic seizures, 14, 22, 43, 43f, 146
features, 147–152
occurrence, 17
electromyography (EMG) electrodes, 32
electrooculography (EOG) electrodes, 32
embryonic development of cerebral cortex, 1–2
encephalitis, 84, 152
encephalopathy, 146, 147, 164
infants with neonatal, 24
preterm infants with, 152
energy production, disorders of, 87–88
epilepsy, 164–166
antiepileptic drugs, 166–167
developed, 166
infantile spasms, 167
inflammation in, 185
inflammatory and immune responses in, 180–181, 180r
epilepsy of infancy with migrating focal seizures (EIMFS), 101, 109–110
epileptic encephalopathies, 147
with CDKL5 mutations, 107–109, 108
epileptic seizures, 42f, 43, 100
epileptic syndromes, 40, 154
epileptics, 147
erthropoietin (Epo), 132, 184
event-based assessment, 67
evoked potentials, 157
excitability of cortical neurons, 4, 6
excitatory iGluRs, 174–175
F
familial rectal pain syndrome, 116
fast frequency activity (FFA), EEG, 20, 20
feature extraction stage, NSDA, 58–77, 61
felbamate, 175
filter settings for EEG, 34, 36f
first-line antiepileptic drugs, 129–132
- phenobarbital in combination with interventions, 131–132
- phenobarbitone, 129–130
- phenytoin, 132
focal clonic event, 13
focal cortical dysplasia (FCD), 89
focal tonic event, 13
Fourier analysis, 59–60
to detect seizure, difficulties of, 63f
fragile X mental retardation protein (FMRP), 110
frequencies of neonatal EEG, 58
frequency band, estimating power in, 64
furosemide, 178
G
GABA-A receptors, 6, 8, 175, 177–180, 178f
GABA-B receptors, 6
GABAergic drug, 114
GABAergic interneurons, 1, 185–186
GABAergic neurons, 185
GABAergic signaling, 181
GABA (γ-Aminobutyric acid) receptors, 6–7, 131, 136, 172, 174–175
Garfinkle-Shevell scoring system, 166
genes and epilepsy, 138
genetic aetiologies, 157
gestation neonate, 90
- glial fibrillar acidic protein, 157
global developmental delay, 168
- glutamate, 6, 174
- glutamate receptors (GluRs), 174
- glycine elevation, 87
- gold cup electrodes, 31
grade III intraventricular hemorrhage, 82f
H
haemorrhage due to thrombosis, 156
head ultrasonography, 154
head ultrasound, 77, 82, 84, 120
hemimegalencephaly (HME), 90
hemorrhagic venous infarcts, 82, 83/
herpes simplex virus (HSV), 84
HIE. See hypoxic-ischemic encephalopathy (HIE)
high frequency filter (HFF), EEG, 34
high-frequency oscillatory ventilation (HFO), 37f
high-pass finite response filter, 34
high-voltage hypsarrhythmia, 43
‘honeymoon period’, seizure freedom, 108
hourly seizure burden (HSB) trend, 71f
HSV encephalitis, 84, 85f
human expert annotation vs. NSDA, 66f
hyperammonaemia, 135
hypercKplexia, 116
hyperemia, 79
hypermotor-tonic-spasms sequence, 108
hypoglycaemia, 85–86, 86f
hyponatremia, 86
hypothalamic abnormalities, 155
hypothermia, 152, 182–183
    xenon and xenon in combination with, 183–186
hypoaxia-ischemia, cascade of injury from, 173
hypoxic-ischemic encephalopathy (HIE), 22, 116,
    122, 128, 152, 154, 163, 180, 182
hypoxic ischemic injury (HII), 78–80
hypsarrhythmia, high-voltage, 43

I
ictal alpha seizure pattern, 152
ictal EEG, 100–101, 102f, 103, 104f
ictal fraction, 22
ifenprodil, 175
IL-1receptor/Toll-like receptor (IL1R/TLR) system,
    180–181
immature brain, impairment of, 146
inborn errors of metabolism (IEMs), 86–89,
    137–138
independent component analysis method, 64
infantile refsum disease, 88
infantile spasms, 155, 167
infants
    with ECD, 19
    with EME, 106
    monitoring at high risk, 51
    morphological changes in cortical neurons, 2–4,
        2f, 3f
    with neonatal encephalopathy, 24
    preterm, 82, 119
    subclinical seizures detection, 46–47
    term, 82
infants with NS, neurodevelopmental outcomes,
    146
    aetiology, 152–154, 155f/
    biomarkers, chemical, 157
    EEG, 146–147
    electrocliniical and electrographic features,
        147–152
evoked potentials, 154–157
HIE, 152, 154, 157
morbidity, 146
mortality in, 146
neuroimaging, 154–157
PAIS, 155
recurrent, 147
infection, 83–84
    congenital, 84
    perinatal, 83–84
inflammatory and immune responses in epilepsy,
    180–181, 180f
inflammatory cytokines, 157
inherent trade-off in NSDA, 65
intellectual disability, 167–168
interictal EEG, 100–101, 105f
interleukin (IL), 157
intermittent events, neonatal seizures, 56
international 10-20 system, 32, 32f, 44, 47–48
International League against Epilepsy (ILAE),
    13–14, 101
inter-observer agreement, 70
intracranial haemorrhages, 155
intraventricular haemorrhages (IVHs), 46–47,
    154
ionotropic glutamate receptors (iGluRs), 174
    groups, 174
    and therapeutic targets of neonatal seizure,
        174–175

J
jitteriness, 115

K
kainite receptors, 175
KCC2 (potassium chloride co-transporter
    isoform 2), 179
    depolarizing action of GABA, 6
    in immature brain, 131
    profile of, 178
KCNO2 encephalopathy, 103–105
KCNO2 mutations, 155
ketogenic diet, 110, 138
kynurenic acid receptor, 6

L
lactate in urine, 157
lamotrigine, 136
Leigh syndrome, 87
lethargy or coma, 163
levetiracetam (LEV), 110, 133–134, 182
lidocaine, 129, 134–135
limited electrode array, 32, 32f
lorazepam, 134
low frequency filter (LFF), EEG, 34
 Index

M
magnetic resonance angiography, 81
magnetic resonance imaging (MRI), 76–77, 154
of brain, 121
near-total brain injury on, 165
in newborn infant, brain, 78f
magnetic resonance spectroscopy, 121
magnetic resonance venography, 82
magnetoencephalography (MEG), 93–94
malformations of cortical development, 89–91, 156
FCD, 89
HME, 90
PMG, 90–91
maternal illness during pregnancy, 119
median non-seizure agreement rate, 70
median seizure agreement rate, 70
melatonin, 132, 184–185
memantine, 175
meningitis, 84, 152
Menkes disease, 88
metabolic abnormalities, 85–89
hypoglycemia, 85–86, 86f
hyponatremia, 86
IEM, 86–89
transient, 85
metabolic disorders, 87–89, 137–138
metabolic etiology, 106
metabotropic glutamate receptors, 6
midazolam (MDZ), 129, 134
middle cerebral artery (MCA), 81
migrational abnormalities, 156
modulators of cation-chloride co-transporters, 131–132
montages for EEG, 34, 36f, 57
morphological abnormalities on neonatal
              neuroimaging, 156
mortality of preterm neonates, 163
motor automatisms, 115–116
multichannel neonatal EEG, interpretation of, 56
multiple-channel v-EEG, 147
Munc18-1 gene, 107
myoclonic encephalopathy, 105–107, 147
myoclonic jerks, 115
N
near infrared spectroscopy (NIRS), 93
needle electrodes, 31–32
NEMO clinical trial, 184
neonatal adrenoleukodystrophy, 88
neonatal brain, injury manifestations, 164f
neonatal cerebral cortex. See cerebral cortex, neonatal
neonatal encephalopathy, 163
neonatal hypoglycaemia, 156
neonatal intensive care units (NICUs), 41, 56, 70, 101, 163
international survey of, 116–117
newborn infant admitted to, 80f
neonatal-onset epilepsies, 100
neonatal period, 1
neonatal seizure detection algorithms (NSDAs), 58–72
aim of, 58
annotation of EEG recording, 65, 66f
classification, 64–65
classifier in, 65
feature extraction, 58–77, 61f
output, 70, 71f
performance metrics, 67, 68f–69f
pre-processing, 58
structure of, 58
neonatal seizures (NS), 56, 122, 146
accurate diagnosis, 114–117
AEDs for, 130f
aetiologies, 117–118, 118f, 128
analysis of EEG for detection of, 59f
behavioral effects, 168
takes, 12, 155
clinical examination, 119–120, 119f
events, 56
examples of, 14, 14f, 15f, 16f, 62f
imaging findings in causes of, 77–93, 79f
imaging studies, 120–122
investigation, 118–120, 120f, 121f
mortality, 56
non-epileptic movements, 117f
occurrence, 114
prevalence of, 12
resistive indices, 76
therapy of. See treatment of neonatal seizures
universal agreement, 56
see also seizure(s)
neonatal-trained technologist, 32
neonates
with BFNS, 101
EEG seizures in, 14, 14f, 15f, 16–17, 16f, 18f, 19, 19f
electrographic seizure, 151
focal clonic seizures, 150
gestation, 90f
with multifocal seizures, 119
neurocritical care, 122
neuroprotection of, 122
phacomatoses in, 92f
sedation, 77
therapeutic cooling in, 122
see also infants
neurodevelopmental impairments, 163
neurodevelopmental outcomes of NS, 163–164
behavior, 168
cerebral palsy, 167
epilepsy, 164–166
pyridoxine-dependant epilepsy (PDE), 137, 154
pyridoxine-dependant seizures, 22
pyruvate dehydrogenase deficiency, 87

**R**
radial migration of neurons, 1
randomised control trials (RCTs), 128–129
receiver operator characteristics (ROC), 66
refractory epilepsy, 108
refractory neonatal seizures, 156–157
repetitive stereotypical movements, 115–116
resampling process, 58
respiratory chain disorders, 87
Rett syndrome, 107
rhythmic clonic jerking, 115
Rice and Vannucci model, 173

**S**
S100beta, 157
Sarnat encephalopathy scale, 24
saw-tooth pattern, 43, 47
second- and third-line antiepileptic drugs, 133–135
  benzodiazepines, 134
  LEV, 133–134
  lidocaine, 134–135
seizure(s), 101, 114, 146
  acute, 100
  burden, EEG for, 22
  characteristic of, 59
  differentiating epileptic seizures from, 115–116
  distinctive, 106, 108
  epileptic, 100
  infants with, 154
  neonates with. See neonatal seizures (NS)
onset, 107
  partial, 106
  semiology, 101, 103, 165
  susceptibility in immature brain, 174
seizure detection
  a-EEG/EEG performance for, 47–50, 49r–50r
  alarm, 46f
  algorithm, 57
  infants at high risk, subclinical, 46–47
  sensitivity for, 49
seizure event detector, 51
seizure-induced injury, 166
Selective Norepinephrine Re-uptake Inhibitors (SNRI), 119
sensitivity for detecting seizures, 49
serine/threonine kinase 9 (STK9), 108
single-channel a-EEG, 47–49
single-channel ECG tracing, 32
single-channel NSDA output, 71f
single-channel recording montage, 57
sleep-wake cycling, 41, 42f, 45f
sodium-channel blockers, 105
sodium potassium chloride co-transporter isoform 1 (NKCC1), 131
cation-chloride importer, 6
inhibition with BTN, 178, 183
on inner ear function, 184
in maturing brain, 178–179
mRNA, 178
soluble NSF attachment protein receptors (SNARE), 107
somatosensory evoked potentials, 157
spontaneous electrical activity, 4
sporadic venocapillary malformation, 93
standard v-EEG and a-EEG, 25
Stargazer mutation, 185
startle disease, 116
status epilepticus, 22, 43, 44r, 56, 172
sterile disposable electrodes, 31
structural brain abnormalities, 107
Sturge Weber syndrome (SWS), 93
STXBP1 (syntaxin binding protein 1) gene, 107
subacute necrotizing encephalomyopathy, 87
subarachnoid haemorrhage, 154
sulfite oxidase deficiency, 88
susceptibility weighted imaging (SWI), 81
suspected seizures, 46
Sutcliffe-Sandiper syndrome, 116
symptomatic cerebral venous sinus thrombosis, 152
synaptic density, 4
synaptic plasticity in developing cortex, 4
synaptic vesicle fusion, 107
synaptic vesicle glycoprotein 2A receptor (SV2A), 133
synchronisation likelihood feature, 63

**T**
temporal based assessment, 70
term infants, 82
  with clinical seizures, 48
HIE, 182–183
LEV, 133
textile electrodes, 31
thalamic lesions, 155
therapeutic cooling, 122
therapeutic hypothermia, 131, 147
therapeutic interventions, 31
  EEG for assessment of response to, 22
  therapeutic targets of neonatal seizure, 177r
  antiepileptic drugs, 181–182
  excitatory iGluRs, 174–175
  hypothermia, 182–183
  mechanism of, 179r
thiopentone, 137
Index

thrombosis
  haemorrhage due to, 156
  symptomatic cerebral venous sinus, 152
tonic movements, 116
topiramate (TPM), 129, 135, 182
transforming growth factor (TGF)-β pathway, 181
trauma, 83
treatment of neonatal seizures, 122, 128–139
  challenges for future, 138–139
  drugs and therapies, 135–138
  duration of therapy, 138
  first-line antiepileptic drugs, 129–132
  genes and epilepsy, 138
  pharmacological, 128–129
  second- and third-line antiepileptic drugs, 133–135
tuberous sclerosis complex (TSC), 92
tumor necrosis factor (TNF)-α, 180–181	
two-channel recording, a-EEG, 45
U
ubiquitin carboxyl terminal hydrolase L1, 157
ultrasonography, head, 154
ultrasound, 76–77
  cranial, 120
  head, 77, 82, 84, 120
uncoupling, 40
urea cycle disorders, 89
V
valproate, 135
valproic acid, 182
v-EEG recording, 30
  artefacts on, 33f, 34, 35f, 37f, 38
  duration of, 38
  electrode application, 30–32, 31f
  montages and filters for, 34, 36f
  number of electrodes, 32, 34
  systems for, 34
venocapillary malformations, 93
venous infarct and hemorrhage, 82
ventriculomegaly, 156
video-EEG (v-EEG), 12–26, 114–116, 147
  for assessment of response to therapeutic interventions, 22
  clinical features of electroclinical seizures, 13–14
  for clues to underlying aetiology, 22–23
  continuous monitoring, 25–26
  diagnosis of neonatal seizures, 13–14
  ECD, 19–20
  for estimation of seizure burden, 22
  for prognosis, 23–24
  recommendations for, 25–26
  seizures in neonates, 14, 14f, 15f, 16–17, 16f, 18f, 19, 19f
  standard a-EEG and, 24
vigabatrin, 136
viral CNS infections, 84
vitamin responsive seizures, 137–138

X
xenon, 137
xenon and xenon in combination with
  hypothermia, 183–186
  anti-inflammatory drugs, 185
  bumetanide, 183–184
  cell-based therapies, 185–186
  erythropoietin, 184
  melatonin, 184–185
  x-linked disorder of copper metabolism, 88
Z
Zellweger syndrome, 88
zonisamide, 136